| MeSH term | MeSH ID | Detail |
|---|---|---|
| Epiglottitis | D004826 | 1 associated lipids |
| Furcation Defects | D017823 | 1 associated lipids |
| Pseudolymphoma | D019310 | 1 associated lipids |
| Tenosynovitis | D013717 | 3 associated lipids |
| Corneal Endothelial Cell Loss | D055954 | 1 associated lipids |
| Asymptomatic Infections | D058345 | 1 associated lipids |
| Aphasia, Broca | D001039 | 1 associated lipids |
| Heartburn | D006356 | 2 associated lipids |
| Eisenmenger Complex | D004541 | 1 associated lipids |
| Focal Nodular Hyperplasia | D020518 | 1 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Domingo S et al. | Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. | 1995 | J Chemother | pmid:8904096 |
| Gastearena I et al. | Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. | 1995 | J Chemother | pmid:8904095 |
| Segreti J et al. | In vitro activity of macrolides against intracellular Legionella pneumophila. | 1996 | Diagn. Microbiol. Infect. Dis. | pmid:8902407 |
| Evans LA et al. | Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. | 1996 | Pharm. Res. | pmid:8899856 |
| Three new studies expand understanding of MAC therapy. | 1996 | Am J Health Syst Pharm | pmid:8899122 | |
| Biebuyck XA | Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. | 1996 Sep-Oct | J. Int. Med. Res. | pmid:8895044 |
| Wintermeyer SM et al. | Dirithromycin: a new macrolide. | 1996 | Ann Pharmacother | pmid:8893122 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Watt B et al. | Comparative activity of azithromycin against clinical isolates of mycobacteria. | 1996 | J. Antimicrob. Chemother. | pmid:8889727 |
| Dunn CJ and Barradell LB | Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. | 1996 | Drugs | pmid:8882383 |
| Yeates RA et al. | Interaction between midazolam and clarithromycin: comparison with azithromycin. | 1996 | Int J Clin Pharmacol Ther | pmid:8880291 |
| Wenisch C et al. | Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. | 1996 | Antimicrob. Agents Chemother. | pmid:8878577 |
| Powers JL | Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878244 |
| Khurana CM | A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878243 |
| McLinn S | A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878242 |
| Aronovitz G | A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878241 |
| McCarty J | A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878240 |
| McLinn S and Williams D | Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media. | 1996 | Pediatr. Infect. Dis. J. | pmid:8878239 |